| Filed On | Filing |
|---|---|
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition
Third quarter 2026 net product revenue of $21 million; cash and cash equivalents of $189.2 million as of September 30, 2026 |
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more
ZYNLONTA data to be featured across 5 oral presentations and multiple posters |
| 13 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +1 more
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of October 7, 2026, by and between ADC Therapeutics SA, a société anonyme domiciled in Epalinges, Canton of Vaud, Switzerland, and organized under the laws of Switzerland ... |
| 13 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Second quarter 2026 net product revenue of $18.6 million; cash and cash equivalents of $219.1 million as of June 30, 2026 |
| 02 Jul 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On June 30, 2026, the Board of Directors of ADC Therapeutics SA (the “Company”), with the advice of its independent compensation consultant, approved one-time retention awards (“Awards”) to certain of the Company’s employees, including i... |
| 24 Jun 2026 |
8-K: Regulation FD Disclosure; Other Events
Planned 17% workforce reduction expected to generate annualized estimated savings of approximately $10m, enhancing financial flexibility |
| 03 Jun 2026 |
8-K: Regulation FD Disclosure; Other Events
Forward - Looking Statements This presentation and any accompanying oral presentation have been prepared by ADC Therapeutics SA ("ADC Therapeutics“, “we” or “us”) for informational purposes only and not for any other purpose. Nothing con... |
| 02 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
Section 1 Name, Registered Office, Purpose and Duration of the Company |
| 04 May 2026 |
8-K: Results of Operations and Financial Condition
LOTIS-5 Phase 3 topline data expected in second quarter 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year end |
| 10 Mar 2026 |
8-K: Results of Operations and Financial Condition
LOTIS-5 Phase 3 topline data expected in second quarter 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year-end 2026 |
| 23 Feb 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities
THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWIS... |
| 12 Jan 2026 |
8-K: Regulation FD Disclosure
2 Forward - Looking Statements This presentation and any accompanying oral presentation have been prepared by ADC Therapeutics SA ("ADC Therapeutics“, “we” or “us”) for informational purposes only and not for any other purpose. Nothing c... |
| 08 Jan 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate Updates |
| 05 Dec 2025 |
8-K: Other Events
On December 3, 2025, ADC Therapeutics SA (the “Company”) announced updated data from the ongoing LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA® in combination with the bispecific antibody glofi... |
| 10 Nov 2025 |
8-K: Results of Operations and Financial Condition
Continued progress across LOTIS-7 with updated data anticipated in 2025 and LOTIS-5 with topline data expected in 1H 2026 |
| 14 Oct 2025 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +1 more
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of October 12, 2025, by and between ADC Therapeutics SA, a société anonyme domiciled in Epalinges, Canton of Vaud, Switzerland, and organized under the laws of Switzerland... |
| 30 Sep 2025 |
8-K: Regulation FD Disclosure
Forward - Looking Statements This presentation and any accompanying oral presentation have been prepared by ADC Therapeutics SA ("ADC Therapeutics“, “we” or “us”) for informational purposes only and not for any other purpose. Nothing con... |
| 12 Aug 2025 |
8-K: Results of Operations and Financial Condition
ZYNLONTA® in combination with glofitamab (COLUMVI®) demonstrated overall response rate (ORR) of 93.3% and a complete response (CR) rate of 86.7% in LOTIS-7 across 30 efficacy evaluable patients |
| 12 Jun 2025 |
8-K: Entry into a Material Definitive Agreement; Costs Associated with Exit or Disposal Activities +1 more
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of June 11, 2025, by and between ADC Therapeutics SA, a société anonyme domiciled in Epalinges, Canton of Vaud, Switzerland, and organized under the laws of Switzerland (t... |
| 05 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
Section 1 Name, Registered Office, Purpose and Duration of the Company |
Loading...